Merck & Co., Inc., known as MSD outside of the United States and Canada, and Eisai Co., Ltd. announced that their Phase 3 LITESPARK-012 trial did not achieve its dual primary endpoints of progression-free survival (PFS) and overall survival (OS) for the treatment of advanced clear cell renal cell carcinoma (RCC). The trial evaluated combination therapies involving KEYTRUDA, LENVIMA, and […]















